Psychemedics

Psychemedics AAQS

The The AAQS of Psychemedics (PMDI) as of Oct 16, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Psychemedics has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Psychemedics in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Psychemedics AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
1.00 USD
Jan 1, 2018
1.00 USD
Jan 1, 2019
1.00 USD
Jan 1, 2020
1.00 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
1.00 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
The Psychemedics AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Psychemedics Stock analysis

What does Psychemedics do? Psychemedics Corp, trading under the ticker PMDI, is a U.S.-based company headquartered in Acton, Massachusetts. The company specializes in drug testing services, focusing on the analysis of hair samples to detect the presence of drugs of abuse. With 204 full-time employees, Psychemedics operates within the Health Care sector, specifically in the Health Care industry. The company's primary service involves conducting drug tests and reporting results to clients, including training for sample collection and storage of positive samples for a fee per unit tested. Its testing methodology provides detailed information on the approximate amount of drug ingested and historical data on drug use patterns over time. Psychemedics went public on January 22, 1987, marking the beginning of its journey as a publicly traded entity. The company's website, https://www.psychemedics.com/, serves as a primary source of information for its services and operations. While the company's core business is centered on drug testing, it does not disclose specific product names or additional services beyond the scope of hair sample analysis and reporting. Psychemedics maintains a presence in the U.S. market, with its operations primarily focused on providing reliable and detailed drug testing solutions to its clients. The company's approach to testing emphasizes both the immediate detection of drug use and the ability to track usage patterns over extended periods, offering a comprehensive service for its customers. Psychemedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Psychemedics stock

The AAQS of Psychemedics is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Psychemedics since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Psychemedics

All Key Metrics — Psychemedics